drugset / Trial / NCT04469023

Late Phase II Study of TS-142 in Patients with Insomnia

NCT04469023

Phase 2 Completed 179 enrolled Taisho Pharmaceutical Co., Ltd.
RandomizedParallel-groupTriple-blindTreatment

Summary

This is a randomized, double-blind, multi-center, placebo-controlled, parallel-group exploratory study in patients with insomnia.

Timeline

Start
2020-09-09
Primary completion
2021-11-16
Completion
2021-11-16

Drugs

EvaluationDrugModalityDoseRoute
Subject TS-142 Small molecule 2.5 mg Oral
Subject TS-142 Small molecule 5 mg Oral
Subject TS-142 Small molecule 10 mg Oral

Indications